Every article, report, and earnings note where MDT appears.
Medtronic plc (MDT) rises after reporting fiscal Q4 2026 results that showed stronger revenue growth, standout cardiovascular performance, and upbeat FY27 guidance. Investors are responding to a cleaner growth narrative as the medical device giant signals improving momentum and solid cash generation.
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
Medtronic is showing its strongest top-line growth in a decade, led by cardiovascular and pulsed field ablation momentum. The stock looks like a balanced Buy for moderate-risk investors, though margin pressure and debt keep the turnaround case from being pristine.
Medtronic plc (MDT) rises after posting fiscal Q4 and full-year FY2026 results that beat guidance and showed its strongest annual revenue growth in a decade. The company also raised its dividend and issued upbeat FY2027 guidance, helping investors reprice the stock as a faster-growing medtech name.
No, Neuralink is not publicly traded. Retail investors can’t buy it in a normal brokerage account today, so the realistic alternatives are waiting for an IPO, looking at comparable public medical-device stocks, or—if accredited—private secondary markets.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate MDT ReportCancel anytime